Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacabrutideg in Chinese Patients With B-Cell Malignancies
NCT05294731Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- May 2022
- Primary completion
- Jun 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of tacabrutideg in B-cell malignancy, non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by BeOne Medicines. Started May 2022; status: recruiting.
02
Drugs
tacabrutideg
03
Conditions
B-cell malignancynon-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05294731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294731.